Multiple Sclerosis (MS) Secondary Progressive
7
4
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Home Based Functional Balance Intervention for Multiple Sclerosis
Senolytics for Secondary Progressive MS
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography